AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32807539
Drug: Teaching intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teaching intervention combining lay language, simplified handouts, provision of an unmarked dosing syringe, and teach-back to confirm correct dosing.
Trial: 32669375
Drug: Ganetespib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib (200 mg/m2, days 1 and 15) with pemetrexed (500 mg/m2, day 1) and cisplatin (75 mg/m2, day 1) or carboplatin (AUC 5, day 1)
Trial: 32669375
Drug: Ganetespib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib at MTD (200 mg/m2)
Trial: 34971646
Drug: Peanut allergen
RxNorm normalized name: PEANUT ALLERGEN-DNFP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut allergen powder-dnfp (PTAH) during 300 mg maintenance
Trial: 32654042
Drug: No post-surgical
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No post-surgical treatment (Group B)
Trial: 32214138
Drug: Rosuvastatin (less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (less favorable treatment response)
Trial: 39133200
Drug: secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 300 mg
Trial: 33509804
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg metformin
Trial: 33509804
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg metformin
Trial: 33509804
Drug: Metformin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (both dosages)
Trial: 32320773
Drug: Curettage and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curettage and imiquimod cream
Trial: 33280441
Drug: Astragalus membranaceus
RxNorm normalized name: Astragalus membranaceus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus membranaceus polysaccharide (APS) treatment
Trial: 32903261
Drug: Oral stimulation
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral stimulation program
Trial: 32700919
Drug: Indigenously adapted
RxNorm normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indigenously adapted cognitive‐behavioral therapy for excessive smartphone use (IACBT‐ESU)
Trial: 36251032
Drug: L-asparaginase Medac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase Medac (historical control)
Trial: 32213316
Drug: Colistin (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin (9 million units loading dose, followed by 4.5 MU twice daily maintenance dose)
Trial: 34582552
Drug: 1 cup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cup of coffee + 2 CBPCC twice daily (PC)
Trial: 33484509
Drug: Physiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy with manual therapy
Trial: 34346946
Drug: Topical fluoride
RxNorm normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoride varnish application (Duraphat; Colgate)
Trial: 32858717
Drug: Massage (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage (daily 30-minute massage for 7 days)
Trial: 32858717
Drug: Control (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (daily 30-minute restriction of nonessential caregiving for 7 days)
Trial: 34936740
Drug: Multicomponent diagnostic
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent diagnostic strategy (on-site molecular testing, guided restructuring of clinic workflows, monthly feedback of quality metrics)
Trial: 32120028
Drug: Liothyronine (L-T3)
RxNorm normalized name: L-T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liothyronine (L-T3) 75 mcg total daily dose (TDD)
Trial: 38204957
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups combined
Trial: 34959798
Drug: Glucose beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose beverage (125 mL semi-skimmed milk and 50 g glucose)
Trial: 34959798
Drug: Intermittent sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent sucrose beverage (125 mL semi-skimmed milk and 50 g sucrose)
Trial: 34959798
Drug: Sucrose beverage
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose beverage (125 mL semi-skimmed milk and 50 g sucrose)
Trial: 34959798
Drug: Isomaltulose beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomaltulose beverage (125 mL semi-skimmed milk and 50 g isomaltulose)
Trial: 37752466
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment
Trial: 36304565
Drug: CYP2D6 genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2D6 genotype treatment (G)
Trial: 32662840
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy at a power of 2 J/cm2 with a total of 4-6 J energy over each implant
Trial: 34937512
Drug: Recombinant follitropin/lutropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant follitropin/lutropin alfa within the protocol of applying gonadotropin-releasing hormone antagonists
Trial: 35007129
Drug: LSVT‐1701, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSVT‐1701, 6 mg/kg single dose
Trial: 35007129
Drug: LSVT‐1701, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSVT‐1701, 1.5 mg/kg twice daily for 4 days
Trial: 35007129
Drug: LSVT‐1701, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSVT‐1701, 3 mg/kg twice daily for 4 days
Trial: 35007129
Drug: LSVT‐1701, 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSVT‐1701, 4.5 mg/kg twice daily for 4 days
Trial: 33409684
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of meropenem (3 g daily) for 48 hours
Trial: 33409684
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose of meropenem based on Cockcroft‐Gault equation
Trial: 33409684
Drug: Standard and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard and adjusted doses of meropenem
Trial: 32114502
Drug: Acalabrutinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib monotherapy (100 mg twice daily)
Trial: 32114502
Drug: Acalabrutinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib combined with pembrolizumab (200 mg on day 1 of each 3-week cycle)
Trial: 33681744
Drug: Intramuscular olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular olanzapine
Trial: 32385647
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml sodium chloride and 20 mg furosemide
Trial: 32385647
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml sodium chloride and 40 mg furosemide
Trial: 32385647
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml sodium chloride
Trial: 32648395
Drug: herb-separated moxibustion
RxNorm normalized name: serrated swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: herb-separated moxibustion combined with budesonide nasal spray (rhinocort), 64 μg each spray, twice daily for 4 weeks
Trial: 32648395
Drug: budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide nasal spray (rhinocort), 64 μg each spray, twice daily for 4 weeks
Trial: 35691371
Drug: 4-month relational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month relational agent coupled with AliveCor Kardia for heart rate and rhythm monitoring
Trial: 33983076
Drug: Manual preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual preparation of saline syringes
Trial: 35303929
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with propofol and intravenous lidocaine
Trial: 35303929
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with sevoflurane and intravenous lidocaine
Trial: 33308131
Drug: Biological therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological therapies
Trial: 32224233
Drug: Oral antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antidiabetic drugs (glyburide, metformin, or pioglitazone)
Trial: 32224233
Drug: ETA-receptor blockade
RxNorm normalized name: Blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETA-receptor blockade
Trial: 35974101
Drug: Treatment-related mortality
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related mortality
Trial: 35449028
Drug: High-dose quadrivalent
RxNorm normalized name: Fluzone High-Dose Quadrivalent PF 2020-2021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose quadrivalent influenza vaccine
Trial: 35115339
Drug: Salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 200 µg
Trial: 33624798
Drug: VVZ-149 Injections
RxNorm normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVZ-149 Injections (10-hour intravenous infusion)
Trial: 33247955
Drug: berotralstat 150
RxNorm normalized name: berotralstat 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: berotralstat 150 mg
Trial: 33247955
Drug: berotralstat 110
RxNorm normalized name: berotralstat 110 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: berotralstat 110 mg
Trial: 32588153
Drug: Daikenchuto (DKT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daikenchuto (DKT) 15 g per day during the perioperative period
Trial: 33934476
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement and topical solution containing nanosilicon
Trial: 35981135
Drug: BROAD light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BROAD light therapy (very brightly illuminated room for at least 6 hours per day for 4 weeks)
Trial: 34304969
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care and exercise (3-weekly 40 min sessions of unsupervised, moderate-intensity home rowing program over 3 months)
Trial: 32147878
Drug: Anatomical occlusal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatomical occlusal reduction with round shoulder preparation (Group OS)
Trial: 32147878
Drug: No preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preparation of tooth (Control group)
Trial: 32147878
Drug: Anatomical occlusal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatomical occlusal reduction with round shoulder preparation and central groove (Group OSG)
Trial: 36414518
Drug: local neck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local neck treatment (NT) + JPS/oculomotor exercises (JPS/OC)
Trial: 36414518
Drug: local neck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local neck treatment (NT) + balance exercises
Trial: 36414518
Drug: all treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all treatments (NT + JPS/OC + balance exercises)
Trial: 36414518
Drug: local neck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local neck treatment (NT)
Trial: 33798455
Drug: Pirfenidone (267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (267 mg three times per day in week 1, 534 mg three times per day in week 2, and 801 mg three times per day thereafter)
Trial: 35314480
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Tolvaptan + Hydrochlorothiazide)
Trial: 32541171
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 ointment applied twice a day for 8 weeks
Trial: 32541171
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied twice a day for 8 weeks
Trial: 36082248
Drug: Maraviroc 150
RxNorm normalized name: maraviroc 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc 150 or 600 mg/day
Trial: 32513299
Drug: Anluohuaxian Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anluohuaxian Pill
Trial: 32513299
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (basic therapeutic drugs for COVID-19)
Trial: 34751506
Drug: Routine daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine daily activities (Control group)
Trial: 32597619
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate supplementation (0.3 g/kg per day for 7 days)
Trial: 34369695
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment with filiform needles inserted perpendicularly, 3 mm in depth, with electric stimulation (2 Hz, 30 min, 3 times a week for 14 treatments)
Trial: 34369695
Drug: Placebo needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo needling method (needle not inserted through skin) with electric stimulation (2 Hz, 30 min, 3 times a week for 14 treatments)
Trial: 32699168
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg once per day
Trial: 32699168
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg once per day with CPAP
Trial: 34034929
Drug: CNS-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS-directed therapy
Trial: 37061656
Drug: DMF 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMF 240 mg twice daily
Trial: 34161776
Drug: REGEN-COV (two-antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGEN-COV (two-antibody combination)
Trial: 34161776
Drug: Single monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single monoclonal antibody treatments
Trial: 34161776
Drug: Dual or
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual or triple antibody combinations (in vitro studies)
Trial: 34340242
Drug: Text-based reminders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text-based reminders delivered one day after notification of vaccine eligibility
Trial: 34340242
Drug: Text-based reminders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text-based reminders delivered eight days after notification of vaccine eligibility
Trial: 34340242
Drug: First reminder
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First reminder designed to induce feelings of ownership over the vaccine dose
Trial: 34340242
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of first reminder with a video-based information intervention
Trial: 35757330
Drug: Shenqisuxin granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqisuxin granule (SQSX) plus conventional treatment
Trial: 33188136
Drug: JAK inhibitors
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAK inhibitors (JAKi)
Trial: 34269398
Drug: Specific vasoactive
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific vasoactive therapy
Trial: 34269398
Drug: Underlying heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Underlying heart and lung disease treatment
Trial: 35719836
Drug: Lycii Fructus
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lycii Fructus extract (LFE) 900 mg/day
Trial: 32899031
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue plasminogen activator thrombolytic therapy
Trial: 33354769
Drug: Daily smartphone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily smartphone-based monitoring including a feedback loop
Trial: 35332521
Drug: Ultrasound-guided proximal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided proximal suprascapular nerve block with 5 ml ropivacaine 7.5 mg/ml
Trial: 35332521
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml isotonic NaCl)
Trial: 33106167
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care and 200 ml convalescent plasma (CP)
Trial: 33106167
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care and 400 ml convalescent plasma (CP)
Trial: 33106167
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care and 200 ml CP
Trial: 33106167
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care and 400 ml CP
Trial: 34236768
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose enoxaparin
Trial: 34236768
Drug: Standard prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylactic dose enoxaparin
Trial: 35483181
Drug: Intrapersonal consequences
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapersonal consequences (e.g., sad mood)
Trial: 34302120
Drug: Total Diet
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Diet Replacement (TDR) for 8 weeks, followed by food-reintroduction over 4 weeks, with weekly behavioral support for 8 weeks, bi-weekly for 4 weeks, then monthly for 3 months
Trial: 32784257
Drug: PLACEBO (Sham)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO (Sham) treatment
Trial: 36279266
Drug: Low Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Level Laser Therapy (LLLT), administered three times a week for 3 weeks
Trial: 36279266
Drug: Extracorporeal Shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shock Wave Therapy (ESWT), administered once a week for 3 weeks
Trial: 34120463
Drug: Cream with
RxNorm normalized name: CREAM WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream with lipid nanoparticles and vitamin E (Group A)
Trial: 34120463
Drug: Cream without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream without nanoparticles nor vitamin E (Group B)
Trial: 34120463
Drug: Cream with
RxNorm normalized name: CREAM WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream with nanoparticles without vitamin E (Group C)
Trial: 32993355
Drug: Diet 2
RxNorm normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 2 (SFSe) with 12.605 mg/kg Se additive
Trial: 32993355
Drug: Diet 4
RxNorm normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 4 (USFSe) with 12.605 mg/kg Se additive
Trial: 32026826
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (HA+HS with oscillatory‐PEP)
Trial: 34543687
Drug: Intensive BP
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive BP treatment (systolic BP <120 mm Hg)
Trial: 34543687
Drug: Standard BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BP treatment (systolic BP <140 mm Hg)
Trial: 34696811
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (brief counseling sessions and low-dose physical activity recommendations)
Trial: 33025448
Drug: Community pharmacists'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community pharmacists' knowledge regarding malaria and its treatment
Trial: 33025448
Drug: Community pharmacists'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community pharmacists' practices regarding antimalarials dispensing
Trial: 33025448
Drug: Barriers to
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barriers to effective contribution in malaria prevention and treatment